Finn
MIR Industrial Technology · Nuclear · Radiation safety · Medical devices · Thesis updated November 15, 2026

Surging nuclear orders tempered by profit margin reset

01 Running thesis

Explosive nuclear growth meets profit trade-offs

Mirion is riding a massive wave of nuclear power investment. In Q3 2026, the company reported a record $1.25 billion backlog. Management cited clear demand drivers, including catch-up capital spending, plant life extensions, and digital transformation. Total revenue grew 24.5% year over year to $277.8 million. Nuclear power orders grew 105% organically, cementing the company as a key supplier for the industry.

The bull case focuses on this unprecedented revenue visibility. Mirion is becoming a default partner in the small modular reactor race, securing $54 million in year-to-date orders across 11 different reactor designers. Proposed regulatory rules for 40-year plant life extensions provide decades of further visibility, helping to derisk the company's aggressive growth projections.

The bear case centers on the cost of this growth. Management recently withdrew their 2028 EBITDA margin target of 30%. They chose to sacrifice near-term profits to heavily fund AI and cybersecurity initiatives, while also dealing with slower margin realization from the Paragon acquisition. This margin reset may alienate investors looking for operating leverage, especially since the Medical segment is still dealing with a prolonged sluggish stretch.

Oct 2026→Q3 2026 results showed massive nuclear order growth and a record $1.25 billion backlog, but management withdrew their 2028 margin target to fund AI and absorb Paragon costs.
Jul 2026→Q2 2026 backlog reached a record $1.14 billion, up nearly 40%. However, overall organic revenue growth was a soft 1% due to sluggishness in the Medical segment.
Apr 2026▲Q1 orders grew 42% including acquisitions and backlog reached a record $1.1 billion. Paragon also grew revenue 45%, which strengthened the nuclear growth case.
Apr 2026→The Q1 2026 filing showed the tradeoff behind the growth. Nuclear & Safety revenue rose 39%, but operating margin fell to 11.3% because recent acquisitions added costs and amortization.
Feb 2026▼The 2025 Form 10-K added a clearer SMR risk and confirmed $775 million of convertible notes issued in 2025. The nuclear opportunity grew, but the capital structure became more complex.
Feb 2026▲Full-year 2025 results showed record orders of more than $1 billion and a large project pipeline above $400 million. Medical and labs weakness kept the view from becoming fully positive.
Oct 2025▲Management said year-to-date SMR orders had passed the prior two years combined. That supported the nuclear demand case, while U.S. RTQA softness added a new watch item.
Oct 2025→Mirion announced plans to buy Paragon for about $585 million, funded with equity and convertible debt. The deal deepened nuclear exposure but raised integration and dilution risk.
02 Business model

Critical tools for regulated customers

Mirion makes money by selling radiation detection, measurement, monitoring, and safety systems. Its customers include nuclear power plants, defense agencies, research labs, hospitals, and cancer-care centers. These buyers care about safety, approvals, and reliability, making it hard for them to switch suppliers.

The business relies on two main types of revenue. One is recurring flow work, such as replacements, service, dosimetry badges, and software tied to a large installed base. The other is larger project work, such as new plant systems, reactor upgrades, and small modular reactor orders. Project work is valuable, but the timing can be uneven.

Paragon and Certrec pushed Mirion deeper into the nuclear plant life cycle. Certrec helps with licensing and regulatory needs. Paragon helps with obsolescence, parts availability, and engineered solutions. That broader offer helps Mirion win more work, but it also raised the cost and risk of integration.

Medical gives the company a second lane. It sells quality assurance tools for radiation therapy, nuclear medicine equipment, dosimetry services, and newer AI software. This segment was a drag on recent growth, so a lasting recovery is essential for overall margin stability.

03 Product portfolio

Radiation tools across two markets

Growth engine

Nuclear detection and monitoring

These systems help nuclear sites detect, measure, and monitor radiation. Demand is rising as utilities extend plant lives and plan new reactor projects.

Growth engine

Paragon engineered nuclear solutions

Paragon adds safety-related systems, replacement parts, and obsolescence support. This business serves large-scale reactors and emerging small modular reactors.

Steady

Certrec regulatory compliance

Certrec helps nuclear customers with plant licensing and ongoing regulatory work. This makes Mirion useful earlier in a plant's life cycle.

Steady

Defense and research instruments

Mirion sells radiation detection and identification tools to defense, labs, and research customers. This work adds breadth beyond commercial nuclear power.

Option

Radiation Therapy Quality Assurance

RTQA products help make radiation cancer treatment safer and more accurate. New platforms like Daily QA4 Pro aim to boost sluggish hardware sales.

Cash cow

Nuclear medicine and dosimetry

This area includes dose calibrators, software platforms, and personal radiation monitoring services. It supports hospitals and care teams that work around radiation.

Option

AI and oncology software

Mirion is pushing new AI tools like the PlanAI dosimetry platform. These aim to improve workflow, but AI also brings legal, compliance, and competitive risks.

04 Business segments

Nuclear remains the primary driver

Nuclear & Safety70%growing fast
Medical30%flat

Segment shares use approximate Q3 2026 revenue from Mirion disclosures, where Nuclear & Safety generated 70% of revenue and Medical generated 30%.

05 Risk factors

What can break the story

Profit margin expansion stalls

High impact · High odds

Management withdrew their 2028 margin target to fund AI investments and absorb slower Paragon margin growth. If these heavy investments fail to deliver long-term leverage, profitability will suffer.

We watchNuclear & Safety operating margins and commentary on AI spending returns.

Medical segment sluggishness

Medium impact · Medium odds

While margins improved slightly, the Medical segment continues to face a prolonged flat spot in demand. If new product launches like PlanAI fail to gain traction, the segment will drag on company-wide growth.

We watchMedical segment organic revenue growth and RTQA hardware volume.

Deals add sales but limit profit

High impact · Medium odds

Paragon and Certrec have lifted revenue and orders, but integrating them has pressured operating margins. If synergies arrive slowly or integration causes operational hiccups, the growth story may look expensive.

We watchAcquisition-related costs and legacy contract margins over the next four quarters.

SMR orders take longer to convert

Medium impact · Medium odds

Mirion's growth plan depends in part on small modular reactors, which remain an emerging market. The company has order momentum, but SMR customers still face design, regulatory, financing, and buildout risks.

We watchNew SMR awards, customer project delays, and the margin profile of SMR backlog.
06 Quick answers

In one breath

What does Mirion Technologies do?

Mirion sells radiation detection, monitoring, measurement, and safety products. Its main customers are nuclear power plants, defense agencies, research labs, hospitals, and cancer-care providers.

Why is nuclear important to Mirion?

Nuclear and Safety made up roughly 70% of recent revenue. The segment is also where orders are growing fastest after the Paragon and Certrec acquisitions, driven by plant life extensions and digital upgrades.

What is the biggest risk for Mirion stock?

A key risk is that strong nuclear orders fail to translate into high profits due to AI investments and integration costs, or that the Medical segment fails to recover from ongoing sluggish demand.

Is Mirion only a nuclear company?

No. Medical makes up around 30% of revenue and includes radiation therapy quality assurance, nuclear medicine, dosimetry, and oncology software. Still, the company is highly tied to the nuclear industry.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Mirion Q3 2026 earnings transcript
  2. Mirion Q3 2026 Form 10-Q
  3. Mirion Q2 2026 Form 10-Q
08 Explore the industry

Comparable Specialty Industrial Machinery companies

Companies near Mirion Technologies, Inc. in Finn's Specialty Industrial Machinery industry ranking.

Get started with Finn today